This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Common variable immunodeficiency with autoantibodies to B- or T-cells — CVID Type IIIB- 또는 T-세포에 대한 자가항체를 동반한 공통 가변성 면역결핍

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D83.2 (common variable immunodeficiency with autoantibodies to B- or T-cells) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsCVID with autoantibodies, CVID Type III, hypogammaglobulinemia with anti-B-cell autoantibodies, autoimmune lymphoproliferation–immunodeficiency overlap syndrome
C. Adult onsetPossibility of first onset in adulthood: high — CVID with autoantibodies is typically first diagnosed in adulthood (20s–40s) through autoimmune cytopenias or recurrent infections. It is characterized by autoantibodies targeting B cells or T cells, causing a dual immune abnormality.
1. HistoryShares the overall history of CVID. The D83.2 subtype (with autoantibodies) was defined as a clinical subtype through analysis of autoimmune complications in CVID patients and flow cytometry-based B-cell immunophenotyping studies (1990s–2000s). Accumulation of case reports of combined ITP+CVID and AIHA+CVID.
2. CausesMechanism of autoantibody production: Treg dysfunction, failure of B-cell tolerance. Autoantibodies against B-cell surface antigens (CD19, CD20, CD21) or T-cell antigens contribute to lymphocyte depletion while also causing poor immunoglobulin production. Possible association with TACI, LRBA and CTLA4 variants.
3. GeneticsPartial overlap with D83.0 and D83.1. TACI (TNFRSF13B), LRBA and CTLA4 variants reported to be associated with CVID with autoantibodies. Polygenic predisposition and HLA associations (HLA-DR7 autoimmunity-associated haplotype) are also involved.
4. General epidemiologyWithin the overall prevalence of CVID, the subtype with autoantibodies is a considerable proportion given the incidence of autoimmune complications (about 25–30% of CVID). ITP alone is the most common (about 10–15%), followed by AIHA and Evans syndrome.
5. PathophysiologyEscape from B-cell tolerance → production by autoreactive B cells of autoantibodies against B-cell or T-cell surface antigens → antibody-mediated lymphocyte elimination (autophagocytosis, complement activation) → lymphopenia and poor immunoglobulin production → CVID phenotype. Treg dysfunction at the same time.
6. SymptomsRecurrent bacterial infections (sinus, pneumonia), autoimmune cytopenias (ITP, AIHA, Evans syndrome), lymphopenia, splenomegaly, autoantibody-mediated organ damage. Some symptoms overlap with D83.1.
7. SignsReduced IgG + autoantibodies (anti-platelet, anti-red cell, anti-B-cell/T-cell); thrombocytopenia and cytopenias; positive DAT; flow cytometry: reduced CD19+ B cells or inverted CD4/CD8; splenomegaly.
8. ScreeningSerum IgG/A/M; autoantibody panel (anti-platelet, DAT, ANA, anti-dsDNA); complete blood count; B-cell fraction (flow cytometry). Annual autoantibody assessment recommended after CVID diagnosis.
9. DiagnosisStandard CVID criteria + detection of autoantibodies against B- or T-cell surface antigens + confirmation of autoimmune cytopenias. Can be included even if autoantibody-negative when autoimmune cytopenias are confirmed.
10. TreatmentIgG replacement therapy (basic); ITP/AIHA: steroids → rituximab → high-dose IVIG → splenectomy. Abatacept when LRBA/CTLA4 is confirmed. Evans syndrome: combined immunosuppressive therapy. Live vaccines contraindicated.
11. PrognosisVaries with the severity of autoantibody-mediated cytopenias and treatment response. Evans syndrome and severe AIHA are life-threatening. Improvement possible with LRBA/CTLA4-targeted therapy. Pulmonary complications and malignant lymphoma determine the long-term prognosis.
12. PreventionContinue IVIG; live vaccines contraindicated; regular monitoring of autoantibodies and blood counts; early introduction of abatacept when LRBA/CTLA4 is confirmed; prevention of osteoporosis and infection with long-term steroid use.
13. ReferencesMichel M et al. Autoimmune cytopenias in common variable immunodeficiency … and 9 other papers

1. History

D83.2 (common variable immunodeficiency with autoantibodies to B- or T-cells) shares the historical context of CVID as a whole but is a subtype distinguished by the specific immunological mechanism of accompanying autoantibodies. After the concept of CVID was established in the 1950s–70s, case reports of some CVID patients with accompanying immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA) or autoantibodies against lymphocytes gradually accumulated in the 1980s–90s.

In the 1990s, as flow cytometry technology was widely introduced into clinical research, the classification of B-cell immunophenotypes in CVID patients began to be refined. Studies of this period reported that anti-CD19, anti-CD20 or anti-CD21 autoantibodies are detected in some CVID patients and that these autoantibodies may contribute to the numerical reduction of B cells. In other words, it was proposed that in patients with this subtype an extrinsic mechanism is involved, in which B-cell destruction by autoantibodies, rather than an intrinsic B-cell defect (D83.0), causes hypogammaglobulinemia.

The cohort study of autoimmune cytopenias in CVID published in Medicine in 2004 by Michel et al. of Paris, France, systematically established that ITP and AIHA occur in CVID patients at a much higher frequency than in the general population and that Evans syndrome (simultaneous ITP+AIHA) is particularly characteristic of CVID patients. This study highlighted the clinical importance of CVID with autoantibodies and provided the clinical basis for the ICD-10 D83.2 classification.

Since the 2000s, studies on LRBA deficiency and CTLA-4 haploinsufficiency have elucidated the molecular mechanism in some patients with CVID with autoantibodies, followed by reports that abatacept treatment dramatically improves autoimmune complications in these patients (Lo et al., 2015). D83.2 is currently understood as a distinct immunological subtype of CVID in which autoantibodies against B or T cells contribute to lymphopenia and antibody deficiency.

2. Causes

The characteristic pathophysiology of D83.2 is that autoantibodies against B-cell or T-cell surface antigens eliminate lymphocytes, causing immunodeficiency. This is an extrinsic immune mechanism distinct from D83.0 (intrinsic B-cell developmental defect) or D83.1 (T-cell regulatory dysfunction).

The root cause of autoantibody production is escape from B-cell tolerance. Normally, autoreactive B cells are eliminated in the bone marrow by central tolerance (receptor editing, clonal deletion) and are controlled in the periphery by anergy or clonal deletion. In CVID patients, these B-cell tolerance mechanisms are incomplete, so autoreactive B cells are activated in the periphery and produce autoantibodies against surface molecules of B cells or T cells (e.g., B-cell markers such as CD19, CD20 and CD21, or T-cell markers such as CD4 and CD8). The autoantibodies produced bind to the corresponding lymphocytes and eliminate them through complement activation and antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent phagocytosis by phagocytes (macrophages, dendritic cells). This autoantibody-mediated lymphocyte elimination leads to reduced B-cell numbers → poor immunoglobulin production → the CVID phenotype.

Genetic predispositions contributing to autoantibody production include LRBA deficiency, CTLA-4 haploinsufficiency, TACI variants and polygenic predisposition. In LRBA deficiency and CTLA-4 abnormalities, Treg dysfunction leaves autoreactive B cells and effector T cells unchecked and promotes autoantibody production. In terms of HLA associations, there are reports that HLA haplotypes with an autoimmune tendency (e.g., HLA-DR7, HLA-B8-DR3) are more strongly associated with autoimmune complications in CVID. Environmental factors (viral infections, molecular mimicry) have also been proposed as triggers of autoantibody production.

When the autoantibody target is B cells, B-cell numbers decrease markedly and immunoglobulin production falls; when the target is T cells, the number of CD4+ or CD8+ T cells decreases and overall adaptive immune function declines. This combined mechanism explains the unique dual immune abnormality (antibody deficiency + impaired cellular immunity) of D83.2 patients.

3. Genetics

The genetic basis of D83.2 is heterogeneous, as in CVID as a whole, and no specific single-gene cause is identified in all patients. However, the following is known about genes and genetic predispositions associated with CVID with autoantibodies.

LRBA (4q31.3) deficiency: autosomal recessive. Autoimmune cytopenias (ITP, AIHA, Evans syndrome) are very common in patients with LRBA deficiency, and Treg dysfunction due to loss of CTLA-4 promotes autoantibody production. Anti-platelet and anti-red cell autoantibodies are found at high frequency in patients with LRBA deficiency. CTLA4 (2q33.2) haploinsufficiency: autosomal dominant. Treg dysfunction due to heterozygous CTLA-4 variants enhances autoantibody production, and not only ITP and AIHA but also autoimmune enteropathy commonly accompany it. TACI/TNFRSF13B (17p11.2) variants: autoimmune cytopenias are reported to occur more frequently in CVID patients with homozygous or compound heterozygous TACI variants.

HLA associations: HLA haplotypes associated with an autoimmune tendency may be observed at higher frequency in D83.2 patients. In particular, an association between the HLA-A1-B8-DR3-DQ2 haplotype and autoimmune complications in CVID has been suggested in some studies. Genome-wide association studies (GWAS) for analysis of polygenic predisposition are under way, and combinations of variants in several immune-related genes are presumed to contribute to determining the D83.2 phenotype. Attempts to identify a single-gene cause by whole-exome analysis are recommended, and especially when autoimmune complications are severe, the LRBA, CTLA4 and TACI genes are analyzed first.

4. General epidemiology

D83.2 is the subtype within CVID as a whole (prevalence about 1:25,000–1:50,000) in which autoantibodies target B or T cells, causing lymphopenia and antibody deficiency. According to major cohort studies reporting the incidence of autoimmune complications in CVID patients, ITP occurs in about 10–15% and AIHA in about 5–10% of CVID patients. Evans syndrome is reported at a much higher frequency in CVID than in the general population. Defining D83.2 as the group of patients in whom autoantibodies against B or T cells have been directly detected gives a narrower category, but using autoimmune cytopenias as the criterion, about 20–25% of CVID patients may fall into this category.

The age of onset is most often in adulthood (20s–40s), but it also occurs in some adolescents. Both diagnostic pathways are frequent: ① reduced IgG found on serum Ig measurement for recurrent infections, and ② reduced IgG found during hematology care for ITP or AIHA (with CVID identified as the underlying cause). In the latter case there is a risk of overlooking the accompanying immunodeficiency while appropriately treating the autoimmune cytopenias, so it is recommended to always assess for accompanying autoantibodies at the time of CVID diagnosis and, conversely, to perform serum Ig testing to exclude underlying immunodeficiency in patients with refractory ITP/AIHA.

5. Pathophysiology

The pathophysiology of D83.2 centers on a unique immune self-destruction mechanism in which autoantibodies target B cells or T cells and eliminate these lymphocytes, resulting in fewer immunoglobulin-producing B cells and antibody deficiency.

Normal immune self-tolerance is maintained by central (elimination of autoreactive T cells and B cells in the thymus and bone marrow) and peripheral (Treg suppression, B-cell anergy, clonal anergy) mechanisms. When these self-tolerance mechanisms break down in D83.2, autoreactive B-cell clones are activated in the periphery and produce autoantibodies after passing through the germinal center reaction. When these autoantibodies bind to B-cell surface antigens (CD19, CD20, CD21, CD22, etc.), B cells are destroyed by complement pathway activation (C1q → MAC formation → B-cell lysis), ADCC (Fc receptor-mediated cytotoxicity by NK cells and macrophages) or opsonization and phagocytosis by the reticuloendothelial system of the spleen and liver. Depletion of the B-cell pool exhausts the precursors of IgG-, IgA- and IgM-producing plasma cells, resulting in reduced serum immunoglobulins → the CVID phenotype.

When autoantibodies target T cells (anti-CD4, anti-CD8, etc.), T-cell numbers decrease and partial impairment of cellular immunity also occurs. In this case, features of cellular immune abnormality (some increase in opportunistic infections) may be added to the clinical phenotype of CVID. At the same time, Treg dysfunction (LRBA/CTLA4 abnormalities), hyperactivated effector T cells or B-cell clonal expansion (monoclonal or oligoclonal B-cell proliferation) underlie the production of these autoantibodies. This complex immune disturbance explains the dual immune abnormality in D83.2 in which autoimmune cytopenias (ITP, AIHA, Evans syndrome) coexist with recurrent bacterial infections.

In ITP with autoantibodies against platelets (anti-GPIIb/IIIa, anti-GPIb/IX), in addition to platelet destruction, a mechanism of suppressed platelet production (autoantibodies against megakaryocytes) may be involved. Warm autoantibodies against red cells (IgG type, reactive at 37°C) cause AIHA, which is confirmed by a positive direct Coombs test (DAT). Evans syndrome, in which ITP and AIHA occur simultaneously, is not a simple coincidence but the result of the breakdown of self-tolerance spreading across multiple cell lineages.

6. Symptoms

The clinical symptoms of D83.2 are characterized by the coexistence of infectious complications due to immunodeficiency and cytopenic complications due to autoantibody-mediated lymphocyte destruction.

Infectious complications: As in D83.0 and D83.1, recurrent bacterial pneumonia, chronic sinusitis and bronchiectasis occur. The main cause is increased susceptibility to bacteria due to reduced IgG. IVIG treatment reduces the frequency of infections, but because the immune disturbance is complex, treatment responses vary.

Autoimmune cytopenias: Immune thrombocytopenia (ITP) is the most common. Bleeding tendency (petechiae, ecchymoses, epistaxis, gum bleeding) and a markedly reduced platelet count (below 50,000/μL, in severe cases <10,000/μL) appear, and severe ITP with a risk of intracranial hemorrhage requires emergency treatment. Autoimmune hemolytic anemia (AIHA): fatigue, pallor, jaundice, tachycardia and dyspnea appear, and rapid hemolysis leads to an acute crisis (hemolytic crisis). Evans syndrome: ITP and AIHA occur simultaneously or sequentially, so bleeding tendency and hemolysis appear together, creating a very serious clinical situation. In CVID, Evans syndrome occurs at a frequency tens of times higher than in the general population, is difficult to treat and relapses frequently.

Lymphoproliferative complications: Splenomegaly (autoantibody-mediated lymphocyte destruction and lymphoproliferation within the spleen), hepatomegaly and lymphadenopathy may appear. Splenomegaly reflects immune activation in patients with coexisting ITP and CVID. Rarely, autoimmune neutropenia accompanies it, resulting in trilineage cytopenia.

7. Signs

The physical and laboratory signs of D83.2 combine findings of hypogammaglobulinemia with findings of autoantibody-associated cytopenias.

Reduced serum immunoglobulins: IgG < 5 g/L + reduced IgA and/or IgM. Poor vaccine response. Reduced B-cell numbers (marked reduction of CD19+) or reduced switched memory B cells reflect B-cell destruction by autoantibodies.

Autoantibody test findings: Positive direct Coombs test (DAT) (IgG warm antibody or complement binding, AIHA). Autoantibodies against platelets (anti-GPIIb/IIIa or anti-GPIb/IX, ELISA). Detection of autoantibodies against B-cell surface antigens (anti-CD19, anti-CD20, anti-CD21) (specialized immunoassays). Systemic autoimmune antibodies such as ANA and anti-dsDNA may accompany them.

Blood count and peripheral blood smear: Reduced platelet count, anemia (normocytic hemolytic anemia), increased reticulocytes, spherocytosis, elevated indirect bilirubin, elevated LDH (AIHA). When accompanied by thrombocytopenia, bone marrow examination shows normal to increased megakaryocytes (suggesting peripheral destruction in ITP). When T-cell autoantibodies are present, flow cytometry shows reduced CD4+ or CD8+ T-cell counts.

Physical findings: Petechiae (mucosa, skin), ecchymoses, epistaxis (ITP). Scleral icterus, splenomegaly, pallor (AIHA). Lymphadenopathy and hepatomegaly may accompany them.

8. Screening

Screening for the D83.2 subtype adds autoantibody assessment to standard CVID screening.

Regular autoantibody assessment after CVID diagnosis: After CVID diagnosis, autoantibodies (platelet autoantibodies, DAT, ANA, anti-dsDNA, anti-neutrophil autoantibodies) are measured as a baseline and then followed up annually for early detection of the appearance of autoantibodies and the development of autoimmune complications.

Regular monitoring of complete blood counts: Platelet count, hemoglobin and white blood cell count are measured at every CVID follow-up visit for early detection of cytopenias. If platelets < 100,000/μL or hemoglobin < 10 g/dL occurs, autoantibody testing and differential diagnosis are performed immediately.

Monitoring of B-cell immunophenotype: CD19+ B-cell counts are followed by flow cytometry. If B-cell numbers fall sharply compared with baseline, autoantibody-mediated B-cell destruction is suspected and anti-B-cell autoantibody testing is performed.

CVID screening in patients with refractory ITP/AIHA: In patients with autoimmune cytopenias, especially adults with accompanying recurrent pneumonia or sinusitis, underlying CVID is actively excluded by measuring serum IgG/A/M.

9. Diagnosis

The diagnosis of D83.2 consists of two axes: the standard CVID criteria + confirmation of autoantibodies against B or T cells.

Standard CVID criteria (ESID 2016): IgG ≥2 SD below + reduced IgA/IgM + poor vaccine response + age 4 or older + exclusion of secondary causes.

Detection of autoantibodies: Platelet autoantibodies (MAIPA: Monoclonal Antibody Immobilization of Platelet Antigens; anti-GPIIb/IIIa, anti-GPIb/IX); direct Coombs test (DAT, separate IgG and complement); anti-B-cell autoantibodies (anti-CD19, anti-CD20, anti-CD21 — specialized immunoassays, flow cytometry-based autoantibody detection); anti-T-cell autoantibodies (anti-CD4, anti-CD8 — specialized research tests). Even if autoantibody-negative, the case can be classified as D83.2 if autoimmune cytopenias (meeting ITP criteria, meeting AIHA criteria) are confirmed and the CVID criteria are met.

Differential diagnosis: Differentiation from isolated ITP or AIHA (normal immunoglobulins), Evans syndrome (unrelated to CVID), thrombotic thrombocytopenic purpura (TTP, thrombotic microangiopathy), aplastic anemia, myelodysplasia, drug-induced cytopenias and lymphoma is important. Overlooking CVID by treating only ITP/AIHA without measuring serum Ig must be prevented.

LRBA/CTLA4 genetic testing: In the combination of autoimmune cytopenias + CVID, LRBA protein expression (flow cytometry) and CTLA4 gene sequencing are performed to confirm the indication for targeted therapy (abatacept).

10. Treatment

Treatment of D83.2 combines basic CVID treatment (IgG replacement therapy) with treatment of autoimmune cytopenias.

IgG replacement therapy: Serum IgG is maintained at or above the target level (≥700–800 mg/dL) with IVIG or SCIG to prevent recurrent bacterial infections. High-dose IVIG (2 g/kg) also has a combined effect in the acute treatment of ITP.

Treatment of ITP: For acute severe ITP (platelets < 20,000/μL or bleeding symptoms), steroids (prednisolone 1–1.5 mg/kg/day) + high-dose IVIG (1–2 g/kg) are given immediately. If steroid-refractory or steroid-dependent: rituximab (375 mg/m2, once weekly for 4 doses, or 1,000 mg twice at a 2-week interval), mycophenolate mofetil, azathioprine, thrombopoietin receptor agonists (eltrombopag, romiplostim). Splenectomy is considered a last resort in CVID patients because it greatly increases the subsequent risk of infection with encapsulated bacteria; pneumococcal, meningococcal and Hib vaccination before the procedure and prophylactic antibiotics afterward are mandatory.

Treatment of AIHA and Evans syndrome: Initial treatment with steroids + high-dose IVIG. Rituximab is effective for refractory or relapsing disease. In Evans syndrome, combined immunosuppressive therapy (steroids + rituximab + mycophenolate or azathioprine) is often needed. When LRBA/CTLA4 abnormalities are confirmed: abatacept is introduced first. It has been reported to reduce steroid dependence and prevent relapse.

HSCT: HSCT is considered in severe refractory autoimmune cytopenias or Evans syndrome that does not respond to existing treatments including abatacept.

11. Prognosis

The prognosis of D83.2 depends greatly on the severity of autoantibody-mediated cytopenias and the treatment response. When mild ITP alone is present, long-term management is possible with appropriate treatment, but when severe Evans syndrome develops, treatment resistance is high and relapses are frequent, so life-threatening situations may recur.

In patients with confirmed LRBA or CTLA4 abnormalities, early administration of abatacept has a marked effect on long-term management of autoimmune cytopenias and improves prognosis. Several case reports describe patients who became free of steroid dependence and whose platelet counts and hemoglobin stabilized after abatacept treatment. In such cases, the clinical value of early genetic diagnosis is very great.

In D83.2, as in other CVID subtypes, the increased risk of non-Hodgkin lymphoma, chronic pulmonary complications (bronchiectasis) and hepatic complications (autoimmune hepatitis or granulomas) are important factors determining the long-term prognosis. Regular multidisciplinary follow-up and screening for complications are essential.

12. Prevention

Prevention of D83.2 adds early detection and suppression of autoantibody-related complications to the common CVID prevention principles.

Live vaccines absolutely contraindicated: As a common CVID principle, all live vaccines such as measles-mumps-rubella, varicella, BCG and oral polio are prohibited. Inactivated pneumococcal and influenza vaccines are recommended, but responses may be incomplete.

Continued IVIG administration: The mainstay of preventing infections due to immunodeficiency; high-dose IVIG also has a combined effect in the treatment of acute autoimmune cytopenias.

Regular monitoring of autoantibodies and blood counts: Blood counts (platelets, hemoglobin, white blood cells) are monitored at 3–6-month intervals for early detection of cytopenias. Autoantibodies (DAT, platelet autoantibodies) are tested annually or when cytopenias develop.

Early introduction of abatacept when LRBA/CTLA4 abnormalities are confirmed: Introducing abatacept after genetic confirmation, before or early in the development of autoimmune complications, can prevent the progression of complications.

Prevention of adverse effects of long-term steroid use: When steroids are needed long term to treat autoimmune cytopenias, osteoporosis prevention (calcium and vitamin D, bisphosphonates), monitoring for diabetes, hypertension and infection, and gastric mucosal protective agents should be provided together. Steroid-sparing agents are introduced early whenever possible to minimize long-term steroid exposure.


13. References

  1. Michel M, Chanet V, Galicier L, et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore). 2004;83(4):254–263. DOI: 10.1097/01.md.0000133620.27542.40. PMID: 15232313.

  2. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clinical Immunology. 1999;92(1):34–48. DOI: 10.1006/clim.1999.4725. PMID: 10413651.

  3. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277–286. DOI: 10.1182/blood-2007-11-124545. PMID: 18319398.

  4. Lo B, Zhang K, Lu W, et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349(6246):436–440. DOI: 10.1126/science.aaa1663. PMID: 26206937.

  5. Schwab C, Gabrysch A, Olbrich P, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. Journal of Allergy and Clinical Immunology. 2018;142(6):1932–1946. DOI: 10.1016/j.jaci.2018.02.055. PMID: 29571818.

  6. Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. Journal of Allergy and Clinical Immunology: In Practice. 2016;4(1):38–59. DOI: 10.1016/j.jaip.2015.07.025. PMID: 26563668.

  7. Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008;111(1):77–85. DOI: 10.1182/blood-2007-06-091744. PMID: 17898316.

  8. Oksenhendler E, Gérard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clinical Infectious Diseases. 2008;46(10):1547–1554. DOI: 10.1086/587669. PMID: 18419489.

  9. Seidel MG, Kindle G, Gathmann B, et al. The ESID Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(6):1763–1770. DOI: 10.1016/j.jaip.2019.02.004. PMID: 30776527.

  10. Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology. 2018;38(1):96–128. DOI: 10.1007/s10875-017-0464-9. PMID: 29226301.